Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter

Oncogene

Volumn 26, Issue 5, 2007, Pages 633-640

  Delarue, F L ^a,b   Adnane, J ^a,b   Joshi, B ^a,b,d   Blaskovich, M A ^a   Wang, D A ^a,b   Hawker, J ^a,b   Bizouarn, F ^a,b   Ohkanda, J ^c   Zhu, K ^a,b   Hamilton, A D ^c   Chellappan, S ^a,b   Sebti, S M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Farnesyltransferase inhibitors; Geranylgeranyltransferase inhibitors; HAT association; HDAC1 dissociation; Histone acetylation; RhoB

Indexed keywords

DACTINOMYCIN; GERANYLGERANYLTRANSFERASE I INHIBITOR; GGTI 298; HISTONE DEACETYLASE 1; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ACETYLATION; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; BENZAMIDES; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; METHIONINE; NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEIN PROCESSING, POST-TRANSLATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOB GTP-BINDING PROTEIN; RNA, NEOPLASM; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33846813827     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209819     Document Type: Article

References (43)

1. Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T et al. (2000). Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. Oncogene 19: 5525-5533.
2. Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Munoz-Antonia T. (2002). Suppression of RhoB expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res 8: 2225-2232.
3. Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R et al (2000). RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody. Proc Natl Acad Sci USA 97: 11626-11631.
4. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE et al. (1998). A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18: 85-92.
5. Benjamin D, Jost JP. (2001). Reversal of methylationmediated repression with short-chain fatty acids: evidence for an additional mechanism to histone deacetylation. Nucleic Acids Res 29: 3603-3610.
6. Chaya D, Hayamizu T, Bustin M, Zaret KS. (2001). Transcription factor FoxA (HNF3) on a nucleosome at an enhancer complex in liver chromatin. J Biol Chem 276: 44385-44389.
7. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. (2000). Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 275: 17974-17978.
8. Cox AD, Der CJ. (1997). Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1333: F51-71.
9. Dasgupta P, Betts V, Rastogi S, Joshi B, Morris M, Brennan B et al. (2004). Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein: novel links between apoptotic signaling and cell cycle machinery. J Biol Chem 279: 38762-38769.
10. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. (2003). The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci USA 100: 8758-8763.
11. Du W, Prendergast GC. (1999). Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 59: 5492-5496.
12. Fritz G, Gnad R, Kaina B. (1999). Cell and tissue-type specific expression of Ras-related GTPase RhoB. Anticancer Res 19: 1681-1688.
13. Fritz G, Kaina B. (2000). Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death. Biochem Biophys Res Commun 268: 784-789.
14. Fritz G, Kaina B, Aktories K. (1995). The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem 270: 25172-25177.
15. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. (2003). Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 278: 47853-47861.
16. Gibbs JB, Oliff A. (1997). The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37: 143-166.
17. Gui CY, Dean A. (2001). Acetylation of a specific promoter nucleosome accompanies activation of the epsilon-globin gene by beta-globin locus control region HS2. Mol Cell Biol 21: 1155-1163.
18. Holstein SA, Wohlford-Lenane CL, Hohl RJ. (2002a). Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 277: 10678-10682.
19. Holstein SA, Wohlford-Lenane CL, Hohl RJ. (2002b). Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 41: 13698-13704.
20. Hunt JT, Ding CZ, Batorsky R, Bednarz M, Bhide R, Cho Y et al. (2000). Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)- 3- (phenylmethyl)-4-(2-thienyl-sulfonyl)-1H-1,4-benzodiazepine (BMS- 214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem 43: 3587-3595.
21. Jiang K, Delarue FL, Sebti SM. (2004a). EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 23: 1136-1145.
22. Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S. (2004b). Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 24: 5565-5576.
23. Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW et al. (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145.
24. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. (1997). Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272: 15591-15594.
25. Lebowitz PF, Prendergast GC. (1998). Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17: 1439-1445.
26. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J et al. (1995). Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270: 26802-26806.
27. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. (1997). Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15: 1283-1288.
28. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC. (2000). RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 20: 6105-6113.
29. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P et al. (1998). Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58: 4947-4956.
30. Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V et al. (2004). Loss of RhoB expression in human lung cancer progression. Clin Cancer Res 10: 2742-2750.
31. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. (1995). Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55: 5310-5314.
32. Pan J, She M, Xu ZX, Sun L, Yeung SC. (2005). Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 65: 3671-3681.
33. Prendergast GC. (2001). Actin' up: rhoB in cancer and apoptosis. Nat Rev Cancer 1: 162-168.
34. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. (1997). Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272: 14093-14097.
35. Sebti SM, Der CJ. (2003). Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3: 945-951.
36. Sebti SM, Hamilton AD. (2000). Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Invest Drugs 9: 2767-2782.
37. Sun J, Qian Y, Hamilton AD, Sebti SM. (1998). Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16: 1467-1473.
38. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. (1997). The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 272: 27224-27229.
39. Wang S, Yan-Neale Y, Fischer D, Zeremski M, Cai R, Zhu J et al. (2003). Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene 22: 6204-6213.
40. Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ. (2001). Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol 21: 6820-6832.
41. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ et al. (1997). K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459-14464.
42. Zhang FL, Casey PJ. (1996). Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269.
43. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. (1998). Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 17: 1415-1438.